Drug intelligence / Profile preview

triamcinolone hexacetonide + lidocaine

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Injection
01

Overview

This pharmacological intervention consists of a combination of **triamcinolone hexacetonide**, a potent synthetic glucocorticoid, and **lidocaine**, a local anesthetic. Triamcinolone hexacetonide is utilized for its long-acting anti-inflammatory and immunosuppressive properties, which help reduce tissue swelling and pain at the site of injection. Lidocaine provides immediate, short-term analgesia by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. In the context of clinical research at **Aalborg University**, this combination is administered via ultrasound-guided injection to the calcaneal insertion of the plantar fascia. It is being evaluated as part of a multimodal treatment strategy for **plantar fasciopathy**, often combined with heavy-slow resistance training (HSR) to address both immediate pain relief and long-term structural rehabilitation.

Brand names
LederspanXylocain
Other names
corticosteroid injectionTriamcinolonhexacetonid + Lidocain
02

Targets

GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on triamcinolone hexacetonide + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone hexacetonide + lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call